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Cystic fibrosis (CF) is the most common lethal recessive genetic disease in the Caucasian population. It is
caused by mutations in the CF transmembrane conductance regulator (CFTR) gene that is normally expressed
in ciliated airway epithelial cells and the submucosal glands of the lung. Since the CFTR gene was first
characterized in 1989, a major goal has been to develop an effective gene therapy for CF lung disease, which
has the potential to ameliorate morbidity and mortality. Respiratory syncytial virus (RSV) naturally infects the
ciliated cells in the human airway epithelium. In addition, the immune response mounted against an RSV
infection does not prevent subsequent infections, suggesting that an RSV-based vector might be effectively
readministered. To test whether the large 4.5-kb CFTR gene could be expressed by a recombinant RSV and
whether infectious virus could be used to deliver CFTR to ciliated airway epithelium derived from CF patients,
we inserted the CFTR gene into four sites in a recombinant green fluorescent protein-expressing RSV (rgRSV)
genome to generate virus expressing four different levels of CFTR protein. Two of these four rgRSV-CFTR
vectors were capable of expressing CFTR with little effect on viral replication. rgRSV-CFTR infection of
primary human airway epithelial cultures derived from CF patients resulted in expression of CFTR protein
that was properly localized at the luminal surface and corrected the chloride ion channel defect in these cells.
Cystic fibrosis (CF) is an autosomal recessive genetic disease
that occurs with an incidence of 1 in every 3,400 live Caucasian
births in the United States and is one of the most common fatal
hereditary diseases in the world (47). CF is caused by a muta-
tion in the cystic fibrosis transmembrane conductance regula-
tor (CFTR) gene that encodes a low-conductance ATP- and
cyclic AMP (cAMP)-dependent chloride ion (Cl) channel.
More than 1,500 mutations that can lead to various degrees of
CF have been found in CFTR. The most common mutation
found in individuals of European descent is a deletion of 3
nucleotides in the CFTR gene resulting in the loss of phenyl-
alanine at position 508 of the CFTR protein (F508). This
mutation results in the translation of a protein that folds im-
properly, causing it to be degraded upon exit from the endo-
plasmic reticulum. Since 90% of the mortality caused by CF
results from lung pathology, restoring functional CFTR to the
airways of CF patients remains a goal of gene replacement
therapeutics for the disease. In the lung, CFTR is expressed by
the respiratory epithelium that lines the lumen of the airways,
where it is localized to the apical membrane of ciliated cells
and the submucosal gland ductal epithelium (20, 40, 48).
CFTR is responsible for the movement of Cl ions across the
apical membranes of the airway epithelium and, in combina-
tion with sodium ion (Na) transport, it dictates the volume of
airway surface liquid that facilitates mucus transport and mu-
cociliary clearance. Lack of functional CFTR in the cell mem-
brane decreases Cl ion secretion; a net increase in the intra-
cellular Cl ion concentration is then followed by increased
uptake of sodium (Na) ions by epithelial sodium channels
(ENaCs). This additional intracellular ion concentration re-
sults in a net increase in water uptake into the cell (68). In
patients with CF, the fundamental consequence of CFTR dys-
function in the airway is dehydration of the airway surface
liquid (ASL) and an increase in the viscosity of the mucus
secretions that coat the respiratory tract. This thickened mucus
leads to plugging of the airways, in addition to decreased air-
way clearance, resulting in an increased susceptibility to both
bacterial and viral airway pathogens.
Early in vitro experiments using the available recombinant
adenoviruses (AdV) and adeno-associated viruses (AAV)
showed some efficacy in airway cell transduction (29, 67); how-
ever, the human clinical trials were less promising due to the
low efficiency of CFTR delivery to the appropriate cells and
short-lived CFTR expression, primarily as a consequence of
the innate and adaptive immune responses (28, 34, 39, 90).
Further studies revealed that CAR, the coxsackievirus and
AdV receptor, and heparan sulfate, the AAV receptor, are
both expressed on the basolateral surface of the human airway,
likely providing another explanation for the poor transduction
efficiency of airway cells by these vectors when introduced
apically (7, 62, 77, 92). More recently, AAV serotypes that
transduce the airway epithelium at a much higher rate have
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been identified, and additional improvements have been made
by mutagenesis, capsid shuffling, and directed evolution (24,
36, 52–54, 78, 89). Lentiviral vectors for the delivery of CFTR
to CF patients have also been examined, and improvements
have been made, but efficiency and safety concerns persist (33,
41, 57, 72, 76, 85). Here, we suggest a potential viral vector to
treat CF that naturally targets the airways.
In vitro studies in which CF cells and CFTR-corrected CF
cells have been mixed in measured ratios have determined that
CFTR expression in 6 to 10% of respiratory cells returns Cl
transport to levels similar to those measured in non-CF epi-
thelial cell cultures (2, 42). However, this low level of correc-
tion may not repair some of the other associated defects, such
as sodium hyperabsorption and mucus dehydration (40). Sim-
ilar studies performed by mixing airway epithelial cells from
CF and non-CF patients to create mixed well-differentiated
human airway epithelial cell (HAE) cultures indicated that if
20% of the cells expressed endogenous levels of CFTR, this
correlated with 70% of the Cl channel response measured in
cultures made with 100% non-CF cells (25). More recently,
infection of HAE cultures with a recombinant parainfluenza
virus type 3 (PIV3) vector engineered to express CFTR was
shown to fully correct the Cl transport defect in HAE cul-
tures. In these studies, CFTR delivery to 25% of the surface
airway epithelial cells was required to restore airway surface
liquid volume and mucus transport to normal non-CF levels
(93). Collectively, these in vitro experiments, in relevant airway
cell models, suggest that an effective vector for CFTR delivery
would need to target at least 25% of the airway surface epi-
thelial cells.
Respiratory syncytial virus (RSV) is a single-stranded nega-
tive-sense RNA virus that infects the ciliated cells of the airway
epithelium of the human respiratory tract (94). Most individ-
uals become infected with RSV during the first and second
years of life; however, due to incomplete immunity, individuals
can be reinfected by RSV throughout their lifetimes. In most
cases, infection results in only mild, self-limited, common cold-
like symptoms, although a proportion of primary infections do
involve lower respiratory tract disease. Serious illness, which
typically involves bronchiolitis or pneumonia, is usually re-
stricted to young infants or the frail elderly. Although RSV
infects CF patients at the same frequency that it infects their
age-matched siblings, CF patients tend to develop more fre-
quent lower respiratory tract illness. It has been shown that CF
patients require more frequent hospitalization due to RSV
infection when they are young, but this decreases with age, as
it does for healthy children (32, 87). Since RSV can infect the
lungs of CF patients, it appears that it can not only navigate
through the physical barriers of the normal respiratory tract,
but can also make its way through the sticky and mucus-rich
environment of the CF lung. In addition, RSV has other fea-
tures that suggest it might have advantages as a gene therapy
vector for the delivery of CFTR to the airways of CF patients.
RSV has a tropism for the luminal ciliated cells of the airway,
which are a relevant target for CFTR gene therapy (40, 48),
and RSV has been shown to lack the overt cytopathology of
other respiratory viruses, suggesting that it will not rapidly
destroy the cells that it infects (94). RSV also has the ability to
reinfect, implying that multiple sequential administrations of
an RSV-based vector would be possible.
Here, we tested the utility of RSV as a CFTR gene transfer
vector. The CFTR gene was inserted into four different sites in
the RSV genome to obtain a range of expression levels. The
vector was then evaluated for the ability to deliver CFTR to the
ciliated cells in an in vitro model of the human airway (HAE).
We show that RSV delivered CFTR to ciliated cells and re-
sulted in sufficient transduction efficiency and functional
CFTR expression to fully correct the Cl transport bioelectric
defect in primary HAE cultures derived from CF patients.
These data support continued efforts to explore the utility of
RSV-based vectors as potential gene delivery vectors for the
treatment of CF lung disease.
MATERIALS AND METHODS
Viruses and cells. Recombinant green fluorescent protein (GFP)-expressing
RSV (rgRSV) (38) was used as the vector backbone in this study. All viruses were
rescued and grown in HeLa cells in Dulbecco’s modified Eagle’s medium
(DMEM) supplemented with 10% fetal bovine serum (FBS). All cells were
grown in a humidified incubator supplied with 5% CO2.
Recombinant virus construction and rescue. The full-length RSV cDNA con-
struct, RW30, used as the backbone for CFTR gene insertion, was derived from
the original RSV cDNA (18) with the following modifications: (i) the highly
efficient T7 promoter that initiates the transcript with GGG at its 5 terminus is
followed by a 5 hammerhead ribozyme sequence (1) so that the positive-sense,
antigenomic T7 RNA transcript can be produced efficiently but the ribozyme
removes itself and the GGG, leaving the exact, native 5 terminus; (ii) the Renilla
recombinant green fluorescent protein (RrFP), a PCR product from pFBRrFP
(Stratagene) without mammalian optimization, is inserted as the first viral gene
with a KpnI site following its open reading frame (ORF); (iii) unique restriction
sites are inserted in the intergenic regions flanking each of the membrane-
associated protein genes; (iv) a BsiWI restriction site is inserted following the L
gene that required 3 nucleotide changes, as provided by Rachel Fearns; and (v)
the 3 hepatitis D virus antigenomic ribozyme (59) replaces the hammerhead
ribozyme so that the transcript will have an exact 3 native terminus. These
insertions and mutations were produced in small plasmids by inverted PCR
mutagenesis (14) and moved into the full-length cDNA by standard subcloning
techniques. The positions and sequences of these alterations are listed in Table 1.
The human CFTR cDNA (John Riordan, University of North Carolina
[UNC], Chapel Hill, NC) was first flanked by RSV gene start (GS) and gene end
(GE) sequences, as well as unique restriction sites to enable the insertion of the
gene unit into RW30. A series of plasmids were created containing the GS and
GE sequences from the RSV F gene, internally flanked by SacII and ApaI
restriction sites and externally flanked by PvuI and XhoI, BssHII, XhoI, or
BsiWI restriction sites. The CFTR gene was inserted into these plasmids
using SacII and ApaI. The resulting CFTR gene units were inserted at the
BssHII, XhoI, or BsiWI restriction site in RW30, creating rgRSV-CFTR6,
rgRSV-CFTR10, and rgRSV-CFTR12, respectively (Fig. 1). rgRSV-CFTR2
was created by first inserting the CFTR gene unit into a partial rgRSV
plasmid using PvuI and XhoI. The CFTR gene unit and a genome segment
containing the NS1, NS2, N, and P genes were then cloned into the complete
rgRSV plasmid using the KpnI and BssHII sites. The names of the resulting
plasmids include a number that describes the position occupied by the CFTR
gene relative to the 3 end of the genome.
All viruses were rescued in HeLa cells using the reverse genetics system
described previously (83). Briefly, a plasmid containing a full-length cDNA of the
virus genome, along with support plasmids expressing the RSV N, P, L, and M2-1
genes, was transfected into 6-well plates of 40% confluent HeLa cells. Initial
replication of the plasmids was driven by a T7 polymerase supplied by coinfection
of the cells with vaccinia virus MVA-T7. Once virus replication and spread were
evident, detected by the presence and clustering of GFP-containing cells, the
virus was harvested. Cells were scraped from the plate, pipetted, and vortexed
before pelleting of the cells by centrifugation. The virus-containing supernatant
was then passaged onto successively larger plates to obtain higher-titered virus
stocks. All viruses were amplified, and the titers were determined in HeLa cells.
Western blotting. HeLa cells at 60% confluence in 100-mm dishes were inoc-
ulated with rgRSV, rgRSV-CFTR2, rgRSV-CFTR6, rgRSV-CFTR10, and
rgRSV-CFTR12 at a multiplicity of infection (MOI) of 0.5 or mock inoculated.
The cells were lysed at 72 h postinoculation (p.i.) using 500 l lysis buffer (1%
Triton X-100, 150 mM NaCl, 50 mM Tris, and an EDTA-free protease inhibitor
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cocktail [Roche]). Laemmli sample buffer containing 5% -mercaptoethanol was
added to equal volumes of lysate. Samples were incubated at 37°C for 30 min,
electrophoresed on a 10% SDS-PAGE gel (49), and transferred to an Immo-
bilon-P membrane (Millipore), which was blocked overnight at 4°C with 5% dry
milk in phosphate-buffered saline plus Tween 20 (PBST). The membrane was
probed with CFTR monoclonal antibody (MAb) 596 (John Riordan, UNC)
diluted 1:1,000. A goat anti-mouse peroxidase-labeled secondary antibody
(Chemicon) was used at a dilution of 1:10,000. The blot was developed with
LumiLight chemiluminescent substrate (Roche). Lysate from Calu3 cells, pre-
pared in the same manner, was used as a positive control for CFTR.
Growth curve. Duplicate wells of HeLa cells at 40% confluence in 12-well
plates were inoculated with rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 at an
MOI of 0.1. At the indicated time points, cells from duplicate wells inoculated
with each virus were scraped, collected, and vortexed. The cells were removed by
centrifugation at 2,000  g for 5 min. The virus-containing supernatant was
transferred to a new tube and frozen on dry ice. The titers of all samples were
determined on HeLa cells by counting GFP-expressing cells at 24 h postinocu-
lation.
Generation of CF HAE. Primary human tracheobronchial epithelial cells from
CF (F508 homozygous) and non-CF donors were obtained from tracheobron-
chial tissues by the UNC CF Center Tissue Culture Core under UNC Institu-
tional Review Board (IRB)-approved protocols. The cells were plated at a
density of 250,000 cells per well on permeable type IV collagen-coated Millicells
(0.4-m pore size, 12-mm diameter; Millipore). Cultures were allowed to differ-
entiate at an air-liquid interface for 4 to 6 weeks to form well-differentiated
cultures with morphological characteristics that resembled those of the human
cartilaginous pseudostratified ciliated epithelium in vivo, as previously described
(31, 61).
Inoculation of CF HAE with rgRSV-CFTR. Prior to virus inoculation, the
apical surfaces of HAE were rinsed 3 times with PBS to remove accumulated
apical secretions. The apical surfaces of quadruplicate cultures were then inoc-
ulated with 200 l of rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 (2  105
PFU, 2  105 PFU, and 1  106 PFU, respectively) or mock inoculated and
incubated for 2 h at 37°C. After removal of the inoculum, the HAE were
returned to a humidified incubator until assays were performed.
Quantification of infection of CF HAE cultures. CF HAE inoculated with
rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 (2  105 PFU, 2  105 PFU, and
1  106 PFU, respectively) were photographed with a Leica DMIRB inverted
fluorescence microscope 24 h postinoculation, and en face percentages of GFP-
positive cells were quantified with ImageJ software (NIH) as previously de-
scribed (93).
Quantitation of CFTR and RSV N mRNA following CF HAE inoculation.
Total RNA was isolated from quadruplicate cultures of CF HAE 48 h after
inoculation with rgRSV, rgRSV-CFTR10, rgRSV-CFTR12 (2  105 PFU, 2 
105 PFU, and 1  106 PFU, respectively) or mock inoculation using acid phenol-
guanidine thiocyanate, followed by DNase digestion and further purification
using the Qiagen RNeasy Mini Kit. The first-strand cDNA was synthesized with
oligo(dT) and SuperScript II reverse transcriptase (Invitrogen). Quantitative
PCR was performed using a Roche LightCycler with the Roche FastStart DNA
Master SYBR green I kit according to the manufacturer’s protocols. Levels of
CFTR mRNA were normalized to the level of GAPDH (glyceraldehyde-3-
phosphate dehydrogenase) measured using LightCycler software version 4.0.
Levels of RSV N mRNA in cultures inoculated with rgRSV-CFTR10 and
rgRSV-CFTR12 were compared to the level in rgRSV-inoculated cultures, which
was set to 1.
Immunofluorescent staining. To immunolocalize CFTR in CF HAE inocu-
lated with rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 or mock inoculated, cells
were gently scraped with a pipette tip and then resuspended in PBS before being
pelleted onto glass slides with Cytospin and air dried. The cells were fixed with
4% paraformaldehyde, and then CFTR was detected with anti-human CFTR
mouse MAb 596 and Alexafluor 568-conjugated goat anti-mouse antibody. Cell
nuclei were counterstained with Hoechst 33342 (Invitrogen). Images were taken
with a Leica SP2 laser scanning confocal microscope and processed with Adobe
Photoshop CS2.
Ion transport measurements. CF HAE inoculated with rgRSV, rgRSV-
CFTR10, or rgRSV-CFTR12 (2  105 PFU, 2  105 PFU, and 1  106 PFU,
respectively) or mock inoculated were mounted in Ussing chambers for mea-
surement of transepithelial resistance (Rt) and transepithelial potential differ-
ence (PD) under open-circuit conditions using a Physiologic Instruments voltage
clamp (San Diego, CA) 48 h postinoculation. The electrical potential difference
across the tissue was continuously recorded, and a constant current pulse (2 to 10
A) was applied across the tissue at 1-min intervals to calculate tissue resistance.
From these measurements, the equivalent short-circuit current (Isc) was calcu-
lated. Additional details of Ussing chamber techniques have been published
previously (35). Ussing chamber experiments were performed in bilateral Krebs
bicarbonate Ringer solution (KBR) gassed with 95% O2, 5% CO2. Drugs (amilo-
ride [104 M], forskolin [105 M], and CFTR172 [105 M]) were added sequen-
tially to the indicated final concentration from concentrated stock solutions
(Sigma-Aldrich) to lumenal and/or basal surfaces. CFTR172 (105 M), a potent
small-molecule inhibitor of CFTR, was synthesized according to appropriate
standards and used as previously described (56). Untreated non-CF HAE cul-
tures were tested in parallel as controls.
ASL measurements. At 48 h after inoculation of the CF HAE cultures with
rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 (2  105 PFU, 2  105 PFU, and
1  106 PFU, respectively) or mock inoculation, 25 l of PBS containing 0.2%
Texas Red-dextran (Invitrogen) was added to the apical surface, giving the
cultures an initial ASL height of 20 to 30 m. Images of the ASL were acquired
using laser scanning confocal microscopy (Zeiss model 510). The ASL height was
determined by averaging the heights obtained from the XZ scans of four culture
regions over time. Additional details concerning ASL measurement have been
published previously (82).
RESULTS
Construction and rescue of recombinant rgRSV vectors ex-
pressing CFTR. A CFTR gene unit containing the 4.5-kb
CFTR gene flanked by a set of RSV transcription signals was
inserted into the full-length rgRSV cDNA in four different
TABLE 1. Modifications to the full-length RSV D53 cDNA to produce RW30
Position Sequence
5 hammerhead ribozyme .......................GGGAAA-CGCGTCTGATGAGGCCGTTAGGCCGAAACTCCTCTCCGGAGTC-ACGCGAAAAAa
BssHII in the P-M IGb............................AGGAAAGGGTGCGCGCTGGGGCAAATc




PvuI in the M-SH IG ..............................ATACACATGGCGATCGACATGGGGCA
ApaI in the SH-G IG..............................TTAAAAATTAGGGCCCAACAATGAAC
SacII in the G-F IG.................................CCTTGACCAACCGCGGAGAATCAAAA
XhoI in the F-M2 IG ..............................TTGCATGCCACTCGAGCTTACCATCT
BsiWI in the trailer..................................AATTAAAAATCGTACGATTTTTTAAA
3 hepatitis delta virus ribozyme............GGGTCGGCATGGCATCTCCACCTCCTCGCGGTCCGACCTGGGCATCCGAAGGAGGACGCA
CGTCCACTCGGATGGCTAAG
a The sequence between the hyphens is the 5 hammerhead ribozyme. The first three Gs (italicized) of the transcript are the final 3 Gs of the optimal T7 promoter
and are included in the transcript. The 5 italicized and underlined nucleotides are complementary to the first 5 nucleotides of the mature RNA antigenome.
b IG, intergenic region, between the GE of the previous gene and the GS of the next gene.
c Boldface nucleotides indicate inserted restriction sites flanked by the native sequences to enable their location in the genome sequence.
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positions, creating the plasmid templates for rgRSV-CFTR2,
rgRSV-CFTR6, rgRSV-CFTR10, and rgRSV-CFTR12, which
were numbered according to the CFTR gene position in the
viral genome (Fig. 1A and B). Virus was rescued from multiple
clones of each rgRSV-CFTR cDNA by transfection into HeLa
cells. Similar to rgRSV, rgRSV-CFTR10 and rgRSV-CFTR12
began to spread by 4 days posttransfection, as visualized by
fluorescence microscopy. rgRSV-CFTR2 and rgRSV-CFTR6
required an additional 2 to 4 days to spread and were more
cytotoxic (i.e., they caused more cell death, and the cells in the
culture were visibly less healthy) during this period and subse-
quent early virus passages compared to the other viruses, in-
cluding the parental rgRSV. This increase in cytopathology
could account for the extra time required to rescue these
viruses. By the third passage, however, these viruses caused
cytopathology similar to that of rgRSV-CFTR10 and rgRSV-
CFTR12.
rgRSV can express full-length, mature CFTR. To test
whether these viruses expressed CFTR, we inoculated HeLa
cells at an MOI of 0.5, harvested cell lysates at 72 h p.i., and
assayed for CFTR by Western blotting. As a positive control,
we used lysate from the human lung cell line Calu3, which
endogenously expresses a high level of mature CFTR. HeLa
cells inoculated with rgRSV-CFTR10 and rgRSV-CFTR12 ex-
pressed mature CFTR protein, band C (Fig. 2, lanes 3 and 4),
with more CFTR produced by rgRSV-CFTR10 than by
rgRSV-CFTR12. The immunoreactive lower band detected in
HeLa cells inoculated with rgRSV-CFTR10 and rgRSV-
FIG. 1. rgRSV-CFTR constructs. The CFTR gene, flanked by the RSV GS and GE, was inserted into the rgRSV cDNA at 4 positions.
(A) Sequences flanking the CFTR gene unit in the four constructs. (B) Schematic of CFTR locations within rgRSV-CFTR genomes. The constructs
are named for the position of the CFTR gene relative to the viral promoter at the 3 end of the genome.
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CFTR12 likely represents CFTR in its immature, underglyco-
sylated state. In contrast, rgRSV-CFTR2 and rgRSV-CFTR6
failed to produce full-length, mature CFTR protein. Four
clones of each of these viruses were tested, and none were
capable of expressing full-length, mature CFTR. Representa-
tive clones of rgRSV-CFTR2 and rgRSV-CFTR6 are shown in
Fig. 2 (lanes 1 and 2). No CFTR immunoreactivity was detect-
able in mock-inoculated HeLa cells or in HeLa cells inoculated
with rgRSV alone. These data indicate that mature CFTR can
be expressed from the rgRSV genome but that the location of
the CFTR gene in the genome may impact the integrity of the
CFTR gene unit. In addition, the difference in CFTR expres-
sion levels between rgRSV-CFTR10 and rgRSV-CFTR12 is
consistent with the polarity of RSV expression. Genes further
from the 3 promoter, the only viral transcription promoter,
are expressed at lower levels because a proportion of the poly-
merase falls off the template at each intergenic region.
The observations that rgRSV-CFTR2 and rgRSV-CFTR6
produced little to no full-length CFTR are likely related to the
increased cytopathic effect (CPE) of these vectors during res-
cue. rgRSV-CFTR2 and rgRSV-CFTR6 would have been ex-
pected to express substantially higher levels of CFTR than
rgRSV-CFTR10 and rgRSV-CFTR12 because they bear the
CFTR gene unit in positions closer to the RSV promoter. It is
conceivable that these high levels of CFTR were cytotoxic
during the rescue and early passages of these viruses. The loss
of cytotoxicity upon serial passage might be explained by the
selection of adventitious mutations that block expression of a
functional CFTR protein. This may explain why multiple
clones of the rescued rgRSV-CFTR2 and rgRSV-CFTR6 lost
both their cytopathic phenotype and their ability to express
complete CFTR. Due to their lack of CFTR expression,
rgRSV-CFTR2 and rgRSV-CFTR6 were not further evaluated
in this study.
Growth kinetics of rgRSV-CFTRs. We compared the growth
kinetics of rgRSV-CFTR10 and rgRSV-CFTR12 to those of
rgRSV to determine whether the 4.5-kb CFTR gene insertion
or the position at which it was inserted affected virus replica-
tion. Cells were infected with each virus at an MOI of 0.1, and
the virus yield was determined over 4 days. Although the virus
yield from rgRSV-CFTR10 and rgRSV-CFTR12 seemed to be
delayed by 4 h compared to that from rgRSV, the shapes of all
the curves were similar, particularly during the early phase
(Fig. 3). By 72 h, the yields for all viruses were similar, indi-
cating that the insertion of CFTR delayed virus replication
somewhat but had little effect on the final virus yield. Because
the growth kinetics of rgRSV-CFTR10 were similar to those of
rgRSV-CFTR12, we concluded that the insertion of the CFTR
gene, not its location in the genome, was responsible for the
delay in virus yield. We hypothesize that the 23% increase in
the rgRSV genome length that results from the insertion of
CFTR was causing a delay in virus replication, most likely
due to the additional time needed for the RSV polymerase
to traverse the longer genome, leading to a delay in virus
yield.
rgRSV can deliver CFTR to CF HAE cultures. To determine
whether RSV can deliver CFTR to well-differentiated airway
cells, quadruplicate HAE cultures derived from airway tissue
of CF patients (CF HAE) with a F508 homozygous genotype
were inoculated with 200 l of rgRSV (2  105 PFU), rgRSV-
CFTR10 (2  105 PFU), or rgRSV-CFTR12 (1  106 PFU) or
mock inoculated. These inocula resulted in multiplicities of
infection of 0.2 for rgRSV and rgRSV-CFTR10 and 1.0 for
rgRSV-CFTR12 for ciliated cells in the cultures. At 24 h p.i.,
GFP-positive cells were visible in all infected cultures (Fig.
4A). The transduction efficiencies for rgRSV, rgRSV-CFTR10,
and rgRSV-CFTR12 were 14%, 10%, and 35%, respectively
(Fig. 4B).
To quantify CFTR expression levels, we measured CFTR
mRNA 48 h p.i. from the quadruplicate infected CF HAE
cultures described above and compared it to endogenous
CFTR mRNA from mock-infected cultures. Since the amounts
of CFTR mRNA are the same in F508 CF tissues and
non-CF tissues, the endogenous levels of CFTR mRNA in
these CF HAE cultures would be representative of that in
non-CF cultures. Our data showed that the endogenous CFTR
mRNA levels in these cultures were not altered by rgRSV
infection. However, CF HAE inoculated with rgRSV-CFTR10
and rgRSV-CFTR12 had 94-fold and 64-fold higher levels of
CFTR mRNA, respectively, compared to the levels in CF HAE
FIG. 2. CFTR expression from rgRSV-CFTR. A Western blot
was performed to detect CFTR protein in HeLa cells infected with
rgRSV-CFTR vectors. Band C (190 kDa) represents full-length,
mature CFTR. Band B (150 kDa) represents immature CFTR.
Endogenous CFTR from Calu3 cells was used as a positive control
(lane 5). Lysates from mock-infected HeLa cells and rgRSV-inoc-
ulated HeLa cells were negative controls (lanes 6 and 7). Shown is
a representative blot from four experiments.
FIG. 3. Growth analysis of rgRSV-CFTR vectors. Shown are
growth curves for rgRSV-CFTR10 and rgRSV-CFTR12 compared to
parental rgRSV. Duplicate wells of HeLa cells were inoculated at an
MOI of 0.1 with either rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12.
Virus was harvested at the indicated times and titrated.
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inoculated with rgRSV or mock infected (Fig. 5A). The rela-
tive levels of CFTR mRNA expression by these two vectors
correlated more closely with the genome position of the CFTR
gene and the amount of CFTR protein produced by each virus
in HeLa cells (Fig. 2) than with the proportion of CF HAE
transduced by each virus (Fig. 4B).
To correlate the amount of CFTR mRNA generated by the
vectors with virus replication, we also quantified the relative
levels of N protein mRNA in these cultures (Fig. 5B). RSV N
protein mRNA levels correlated closely with infection effi-
ciency (Fig. 4A), indicating similar amounts of N protein
mRNA production and, therefore, similar levels of replication
for each virus. These data suggest that the levels of replication
of these viruses do not account for the difference in levels of
CFTR mRNA expression. By comparison of the amount of
CFTR mRNA with that of the N mRNA being expressed by
each virus, the rgRSV-CFTR10 vector produced approxi-
mately 4-fold more CFTR mRNA per infected cell than the
rgRSV-CFTR12 vector.
To determine whether the CFTR protein produced by
rgRSV-CFTR10 and rgRSV-CFTR12 was correctly localized
at the apical surfaces of the ciliated CF HAE cells, we immu-
noprobed CF HAE 48 h p.i. for CFTR protein. These studies
confirmed that CFTR protein was produced in ciliated cells by
both vectors and was detected at the apical surface (Fig. 6),
FIG. 4. rgRSV-CFTR infection of CF HAE. Quadruplicate CF
HAE cultures were inoculated with 2.0  105 PFU, 2.0  105 PFU, and
1.0  106 PFU of rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12, re-
spectively. (A) At 24 h postinoculation, GFP expression was detectable
in cultures infected with rgRSV, rgRSV-CFTR10, and rgRSV-
CFTR12, indicating infection (representative images are shown).
(B) The percentages of GFP-positive cells at 24 h p.i. were quantified,
and the results are displayed as means and standard deviations. The
results depicted are representative of two experiments, each including
quadruplicate cultures for each experimental condition.
FIG. 5. Expression of CFTR mRNA in CF HAE cultures infected with rgRSV, rgRSV-CFTR10, or rgRSV-CFTR12 (2  105 PFU, 2  105
PFU, and 1  106 PFU, respectively) or mock infected. Total mRNA was collected from infected and mock-infected cultures 48 h postinoculation
(n 	 4). (A) The amount of CFTR mRNA present in infected cultures was compared to that in mock-treated CF HAE cultures. (B) The amount
of viral N protein mRNA present in cultures infected with the rgRSV-CFTR vectors was compared to that in rgRSV-infected cultures. All results
are shown as means and standard deviations. The asterisks indicate a statistically significant difference (P value 
 0.05) as determined by an
unpaired Student t test. The results depicted are representative of two experiments, each including quadruplicate cultures for each experimental
condition.
FIG. 6. CFTR expression and localization in rgRSV-CFTR-in-
fected CF HAE cultures. At 48 h postinoculation, CF HAE cultures
that were mock infected or infected with rgRSV, rgRSV-CFTR10, or
rgRSV-CFTR12, as indicated, were sectioned and stained for CFTR
with MAb 596, followed by a goat anti-mouse Ig-Alexafluor 568-con-
jugated secondary antibody (red). Nuclei were stained with Hoechst
33342 (blue). Representative images are shown.
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thus recapitulating the localization of endogenous CFTR in
non-CF ciliated HAE, as previously reported (20, 48).
CFTR delivered to CF cells by rgRSV-CFTRs is functional.
To determine whether the CFTR produced by the RSV vectors
was functional as a Cl channel, CF HAE cultures were inoc-
ulated with rgRSV, rgRSV-CFTR10, and rgRSV-CFTR12
(2  105 PFU, 2  105 PFU, and 1  106 PFU, respectively)
or were mock inoculated and assessed for ion channel activity
in Ussing chambers. Two days after virus inoculations, cultures
were mounted in Ussing chambers and ion transport was as-
sessed using previously established methods (35). Briefly, elec-
tric current across the tissue (Isc) in response to applied electric
pulses was measured, while a series of drugs was applied in the
following order: amiloride, a potent inhibitor of Na ion chan-
nels (specifically, ENaCs), was used to prime the cells for
maximal CFTR activity; forskolin, an activator of adenylate
cyclase, was used to maximally stimulate CFTR channel activ-
ity; CFTR172, a potent inhibitor of CFTR, was added to con-
firm the specificity of any forskolin-induced change in Isc; and
UTP, a stimulator of Ca2-activated Cl channels, was added
to activate Cl channels other than CFTR as a positive control.
Representative traces from Ussing chamber experiments are
shown in Fig. 7A. CF HAE infected with rgRSV-CFTR12
exhibited a lower Isc before treatment with amiloride and
therefore a reduced Isc after amiloride treatment, suggesting
that the Na channel hyperactivity exhibited by ENaCs in
these cells was reduced somewhat by this treatment (Fig. 7A
and B). However, due to the lack of other factors involved in
the control of ENaC function, this trend will need to be tested
further to determine if this decrease in ENaC hyperactivity is
significant. CF HAE inoculated with rgRSV-CFTR10 and
rgRSV-CFTR12, however, did show increases in Isc after for-
skolin treatment (Fig. 7A and C). These increases returned to
baseline following treatment with CFTR172 (Fig. 7A and D),
indicating that they can be attributed to the presence of func-
tional CFTR channels provided by rgRSV-CFTRs. When the
magnitudes of the forskolin-induced changes in Isc produced
by rgRSV-CFTR10-, rgRSV-CFTR12-, and rgRSV-infected
cells were quantified and compared in parallel experiments to
that produced in non-CF HAE, infection with rgRSV-CFTR12
resulted in a 25.84  10.76-A/cm2 increase, which is not
statistically different than that seen in non-CF HAE cultures
(16.34  4.26 A/cm2) (Fig. 7C). Although infection with
rgRSV-CFTR10 also resulted in increased forskolin-activated
ion channel activity (6.12  1.23 A/cm2), the increase was not
as great as that in non-CF HAE or CF HAE infected with
rgRSV-CFTR12 (P values of 0.04 and 0.006, respectively). This
suggested that full CFTR correction occurred in response to
rgRSV-CFTR12, but not rgRSV-CFTR10 (which had been
administered at a lower dose and infected fewer cells, as shown
in Fig. 4).
Treatments to measure ASL were performed on CF HAE
cultures 48 h after the cultures were inoculated with rgRSV,
rgRSV-CFTR10, and rgRSV-CFTR12 (2  105 PFU, 2  105
PFU, and 1  106 PFU, respectively) or were mock inoculated,
in order to determine if the RSV-supplied CFTR could im-
prove the maintenance of ASL height. Texas Red-dextran-
labeled PBS was applied to each culture, and the height of this
overlay was measured 48 h later. In CF HAE that had been
mock infected, over half of the fluid was absorbed. In contrast,
FIG. 7. Ion transport properties of CF HAE cultures following inoculation with rgRSV-CFTRs. CF HAE cultures were inoculated with rgRSV,
rgRSV-CFTR10, or rgRSV-CFTR12 (2  105 PFU, 2  105 PFU, and 1  106 PFU, respectively) or were mock infected and were measured for
ion transport properties in Ussing chambers at 48 h p.i. (A) Representative traces of the ISC responses (y axis) in mock-, rgRSV-, and
rgRSV-CFTR-infected cultures in response to sequential treatment with amiloride (Amil) to inhibit ENaCs, forskolin (Fskl) to activate CFTR
activity, CFTR172 to inhibit CFTR activity, and UTP to stimulate Ca2-activated Cl channels as a positive control. (B to D) Maximum changes
in ISC (ISC) in response to individual treatments. (B) ISC of CF HAE after amiloride treatment. (C) Forskolin-induced ISC of CF HAE,
indicating the presence of functional CFTR. (D) ISC of CF HAE following treatment with CFTR172. These results showed that the magnitude
of forskolin-activated changes in CF HAE infected with the RSV-CFTRs was comparable to that in non-CF HAE (n 	 7). All results are shown
as means and standard deviations. “ns” indicates a difference that is not statistically significant (P value  0.05). The asterisk indicates a difference
that is statistically significant (P value 
 0.05), as determined by an unpaired Student t test. The results depicted are representative of two
experiments, each including quadruplicate cultures for each experimental condition.
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cultures infected with rgRSV-CFTR12 were able to maintain
their ASL height, indicating that the CFTR supplied by the
rgRSV-CFTR12 vector was functional as an ion channel and
could also perform its downstream role of equilibrating liquid
absorption from the ASL.
DISCUSSION
Shortly after the identification of the gene encoding CFTR
and the demonstration that mutations in this gene were re-
sponsible for CF, gene therapy approaches began to be ex-
plored for the treatment of CF lung disease, as this was the
primary cause of morbidity in the CF patient. Clinical trials
using viral vectors (AdV and AAV) and non-virus-based vec-
tors (e.g., liposomes) to deliver CFTR cDNA to the airways of
CF patients were determined to be safe but showed little effi-
cacy due to poor transduction of the lumenal epithelial cells of
the airways (4, 11, 28, 39, 62, 63, 69, 84). However, recently,
significant changes have been made to AAV vectors to im-
prove their targeting of the airway epithelium. It will be inter-
esting to see if these new AAV vectors will result in increased
ASL in CF airway cultures, as we have shown here for RSV, as
we consider ASL measurements to be the optimal measure-
ment for determining whether the CF phenotype has been
corrected (24, 52, 53). The pseudotyping of lentiviruses and the
creation of nonintegrating lentiviruses may also make them a
more suitable vector for targeting the airway (3, 5, 12, 46, 70,
72, 86). We have chosen to take a different approach to vector
construction by exploiting a natural respiratory virus, RSV,
which has a natural tropism for the ciliated cells of the airway
lumen. Ciliated cells express CFTR and likely dictate the ma-
jority of airway surface liquid volume regulation (20, 40, 48),
suggesting that they are a logical cellular target for the replace-
ment of CFTR function.
To test our hypothesis that RSV could deliver sufficient
CFTR to ciliated cells to correct the CF bioelectric defect, we
inserted the CFTR gene into four different positions in the
RSV genome to produce different amounts of CFTR. All four
viruses were rescued, but CFTR was expressed only from the
two expected to produce the smallest amounts of CFTR, sug-
gesting that higher levels of CFTR were cytotoxic. Overexpres-
sion of CFTR in fibroblasts has previously been shown to slow
cellular proliferation and possibly to cause an unfolded-protein
stress response, resulting in cell death (88). Overexpression of
a protein by RSV is not, by itself, cytotoxic, since other trans-
genes, such as GFP, can be expressed at a high level from the
first genome position without toxicity. rgRSV-CFTR10 and
rgRSV-CFTR12 were passaged four times in HeLa cells with-
out losing CFTR expression, indicating that they are geneti-
cally stable despite the inclusion of a large gene that is not
necessary for virus replication.
Our data show that 3.5 times more ciliated cells in CF
HAE were transduced with rgRSV-CFTR12 than with rgRSV-
CFTR10, correlating roughly with the viral inoculum (Fig. 4)
and with the amounts of RSV N protein mRNA produced
(Fig. 5B). However, cultures infected with rgRSV-CFTR10
produced 5.3 times more CFTR mRNA than cultures in-
fected with rgRSV-CFTR12 (Fig. 5A). From the N and CFTR
mRNA measurements, we can extrapolate that the CFTR gene
inserted into the 10th position of the RSV genome is tran-
scribed 4 times more efficiently than from the 12th position.
This result illustrates the ability to control the amount of trans-
gene expression simply by changing the gene position in the
RSV genome. Incidentally, the observation that there was only
an 4-fold decrease in CFTR mRNA expression between the
10th and the 12th positions suggests that the presence of the
very large 6.5-kb L gene before the CFTR gene in rgRSV-
CFTR12 did not result in a high level of polymerase fall-off.
During RSV infection, the relative molar amount of L mRNA
that accumulates in infected cells is much smaller than that of
the other RSV mRNAs, a difference that cannot be accounted
for solely by the transcriptional gradient (19). One possibility
was that this difference in mRNA concentration was due to
intragenic polymerase fall-off during transcription of the long
L gene. However, the present finding of only an 4-fold re-
duction in mRNA transcribed from a foreign gene inserted
before the M2 gene and after the L gene indicates that this is
not the case. Some other factor, possibly mRNA instability,
may account for the unexpectedly low accumulation of L
mRNA.
Both rgRSV-CFTR10 and rgRSV-CFTR12 produced func-
tional CFTR, as measured by Cl transport in Ussing cham-
bers, but the magnitude of forskolin-mediated CFTR activa-
tion correlated closely with the number of infected cells rather
than with the levels of total CFTR mRNA being produced.
This result suggests that there is a limit to the CFTR activity
per cell and that this limit had been reached by both vectors.
One possible explanation for this limit on CFTR function in
the presence of CFTR overexpression is that there are a lim-
ited number of CFTR membrane sites and, once these are
occupied, no additional CFTR molecules are allowed in the
membrane and no further effects on intracellular ion balance
are possible. Thus, even though rgRSV-CFTR10 produced
more CFTR per cell (Fig. 2A and 5A), rgRSV-CFTR12 caused
greater overall CFTR function (Fig. 7C) because it was deliv-
ered to more cells in these particular experiments (Fig. 4).
These results are consistent with previous findings indicating
that, as long as CFTR is expressed above endogenous levels, it
is more effective to deliver CFTR to more cells than to express
a larger amount of CFTR in fewer cells (25, 30, 93).
At the MOI used in these experiments, rgRSV-CFTR10
infected 10% of the apical CF HAE (Fig. 4) and exhibited a
cAMP-activated CFTR activity that was 37% of that in non-CF
HAE (Fig. 7C). Similarly, rgRSV-CFTR12 infecting 35% of
CF HAE generated a CFTR response that was statistically
equivalent to that of non-CF cells, though numerically higher.
In both cases, overexpression of CFTR in individual infected
cells led to greater CFTR function per cell than in non-CF
cells. With rgRSV-CFTR12, given its higher input MOI, we
were able to target more than the suggested number of cells
needed to reverse the chloride ion transport defect in the CF
lung (2, 42, 60). Also, the degree of CFTR function provided
by rgRSV-CFTR12 exceeds the amount that is thought to be
needed to reverse many of the other defects in the CF lung,
such as sodium hyperabsorption and mucus thickening (25,
93). Indeed, our results suggest that RSV expression of CFTR
in CF HAE has some effect on ENaC function (Fig. 7B) and
confirm that the ASL is maintained at a higher volume in
cultures infected with rgRSV-CFTR12 (Fig. 8). In addition to
correcting the ASL dehydration phenotype of CF HAE,
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rgRSV-CFTR12 also infected a percentage of cells in the cul-
tures that exceeded the amount (35% versus 25%) speculated
as being required for the correction of other defects (i.e.,
ciliary beat frequency and mucociliary transport efficiency), as
shown in the PIVCFTR vector study (93).
Recently, Sendai virus, a paramyxovirus that naturally in-
fects the airways of mice, was shown to express functional
CFTR in vitro and in vivo in CFTR-deficient mice and was
proposed as a gene therapy vector (26). Generally, when a
virus that naturally infects one species, in this case mice, is used
to infect another, in this case humans, it induces a powerful
innate immune response because viral mechanisms of immune
evasion often do not operate efficiently in a foreign host (10).
In addition to inhibiting virus replication, stimulation of innate
immunity also enhances the adaptive immune response. It is
likely that Sendai virus would not be able to control the innate
response in human cells, resulting in inhibition of virus repli-
cation and stimulation of adaptive immunity. On the other
hand, such a response could be an advantage for a vaccine
vector, and Sendai virus is currently being developed as a
vaccine vector for multiple respiratory viruses (43, 73, 74, 80,
91). RSV suppresses the innate immune response in human
cells via its two unique nonstructural proteins, NS1 and NS2.
These proteins attenuate interferon induction, as well as the
antiviral response caused by interferon (23, 55, 64, 75). The
reduced interferon response to RSV infection may also play a
role in dampening the adaptive immune response to RSV
(22, 50).
RSV infection does elicit a muted adaptive host immune
response that allows repeated infections throughout life with-
out the need for significant antigenic change (8, 37, 71), sug-
gesting that an RSV-based gene therapy vector might be suc-
cessfully readministered. In one study, 7 of 15 individuals could
be infected three or more times over a 26-month period, as
detected by shed virus or a rise in RSV antibody titer. Fur-
thermore, infection can occur without virus shedding, as shown
recently for another paramyxovirus, PIV3, in nonhuman pri-
mates (13). In this case, shed virus may have been neutralized
by antibody, perhaps as the result of a memory response. Re-
peat infections with RSV are usually limited to the upper
respiratory tract, suggesting that the level of preexisting anti-
body is not high enough to be protective but that the memory
immune response is successful at preventing the spread of RSV
from the upper to the lower respiratory tract. However, a
vector delivered by aerosol could be distributed throughout the
lung simultaneously (6, 51), enabling vector infection before a
memory response could be mounted. Furthermore, recent in
vivo data have shown that while previous exposure to RSV
does not prevent reinfection, it instead causes the challenge
infection to become abortive: RSV enters cells and replicates
but fails to generate infectious progeny virions (9), perhaps
because they are neutralized by an antibody recall response.
This situation might be ideal for a gene transfer vector, reduc-
ing the likelihood of cell-to-cell spread and disease symptoms.
In addition, through efforts to develop RSV vaccines, muta-
tions and gene deletions that attenuate the virus have been
identified (21, 44, 45), some of which could be incorporated
into RSV-CFTR vectors to reduce or eliminate pathogenesis.
The observation that CFTR expression from RSV is robust,
and possibly too robust from the second and sixth positions,
indicates that substantial reductions in overall RSV gene ex-
pression could be accommodated while maintaining adequate
levels of CFTR expression to correct ciliated-cell defects. This
suggests that an RSV vector could be attenuated without the
loss of sufficient CFTR expression. Attenuation could also
reduce the immunogenicity of the infecting virus, as has been
found in some clinical trials with live attenuated vaccine can-
didates, and in turn may facilitate reinfection. Further studies
in applicable animal models will need to be performed to
determine the immune response to this vector, as well as its
persistence and its ability to infect upon readministration.
Newly developed models of CF lung disease in the pig and
ferret may provide animal models for testing an RSV-based
vector due to their ability to be infected with RSV and their
similarities in lung physiology to humans (15, 17, 27, 65,
66, 79).
Collectively, our data support further investigation of RSV
as a vector for CF gene therapy. RSV infects the ciliated cells
of both non-CF and CF HAE cultures, thus delivering CFTR
to the appropriate target. rgRSV-delivered CFTR is expressed
correctly at the apical surface and is functional at a level that
recapitulates the Cl channel activity observed in normal HAE
cultures. rgRSV-expressed CFTR also improves ASL dehydra-
tion in CF HAE cultures, thus correcting a hallmark defect of
CF lung disease. The ability to incorporate transgenes into
RSV at various positions to control their expression level and
the immune evasion properties of RSV, as well as the potential
for generating less-cytopathic RSV vectors, further strengthen
the potential of RSV as a gene therapy vector for CF and for
other diseases affecting the airways.
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